The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma
Paula Ghaneh(University of Liverpool), John P. Neoptolemos(University of Liverpool), David Goldstein(New South Wales Department of Health), Richard Jackson(University of Liverpool), Charlotte Rawcliffe(University of Liverpool), Michael Raraty(University of Liverpool), Daniel H. Palmer(University of Liverpool), Andrew Scarfe(Cancer Institute (WIA)), Chloe Smith(University of Liverpool), Jörg Kleeff(University Hospital in Halle), James Melling(Royal Liverpool and Broadgreen University Hospital NHS Trust), Markus W. Büchler(Heidelberg University), Attila Oláh(Semmelweis University), Jakob R. Izbicki(Universität Hamburg), Ross Carter(Glasgow Royal Infirmary), Bengt Glimelius(Uppsala University), Oliver Strobel(Medical University of Vienna), Owain Jones(Royal Liverpool and Broadgreen University Hospital NHS Trust), Juan W. Valle(Cancer Research UK Manchester Institute), Niall C. Tebbutt(Austin Health), Alan Anthoney(St James's University Hospital), Christopher Halloran(University of Liverpool), Trevor F. Cox(University of Liverpool), Markus M. Lerch(Ludwig-Maximilians-Universität München), Fiona Campbell(University of Birmingham), Christos Dervenis(Agia Olga Hospital), Jennifer Shannon(The University of Sydney), Alexander McDonald(Beatson West of Scotland Cancer Centre), Robert Padbury(Flinders Medical Centre), Derek O’Reilly(Manchester Royal Infirmary), Mark Deakin(John Radcliffe Hospital), Julia Mayerle(LMU Klinikum)
Cited by 257
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k